VR Adviser LLC Has $21.97 Million Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

VR Adviser LLC lowered its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 29.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,457,348 shares of the biotechnology company's stock after selling 1,001,297 shares during the period. Astria Therapeutics makes up about 1.5% of VR Adviser LLC's portfolio, making the stock its 18th largest holding. VR Adviser LLC owned approximately 4.35% of Astria Therapeutics worth $21,969,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $41,000. Tower Research Capital LLC TRC lifted its holdings in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 2,766 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $50,000. Virtus ETF Advisers LLC bought a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $65,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $91,000. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Trading Down 3.9%

NASDAQ:ATXS traded down $0.16 on Friday, hitting $3.92. The company had a trading volume of 245,437 shares, compared to its average volume of 371,185. The stock has a market capitalization of $221.22 million, a price-to-earnings ratio of -1.88 and a beta of 0.45. The firm has a 50 day moving average of $4.75 and a two-hundred day moving average of $7.11. Astria Therapeutics, Inc. has a 52 week low of $3.56 and a 52 week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10). As a group, equities analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They set an "outperform" rating and a $26.00 price target for the company. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Cantor Fitzgerald reissued an "overweight" rating and issued a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.